Share

March 22, 2005; 64 (6) Brief Communications

Long-term outcome of endovascular stenting for symptomatic basilar artery stenosis

W. Yu, W. S. Smith, V. Singh, N. U. Ko, S. P. Cullen, C. F. Dowd, V. V. Halbach, R. T. Higashida
First published March 21, 2005, DOI: https://doi.org/10.1212/01.WNL.0000154600.13460.7B
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
660

Share

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Eighteen patients underwent stenting for symptomatic basilar artery stenosis. There were three major periprocedural complications (16.7%) without fatality. At a mean 26.7 ± 12.1-month follow-up, 15 patients (83.3%) had an excellent long-term outcome. Only one patient (5.6%) had moderate disability from recurrent stroke, and two patients died of medical illness at 30 and 36 months after stenting. In this uncontrolled study, stenting appeared to be effective in reducing stroke risk and death and worthy of further scrupulous trial.

View Full Text

AAN Non-Member Subscribers

Purchase access

Letters: Rapid online correspondence

  • Long-term outcome of endovascular stenting for symptomatic basilar artery stenosis
    • Osama O Zaidat, Duke University, Duke University Medical Center, Duke North, Box 3808, Durham, NC 27710
    • Tony P. Smith, Michael J. AlexanderBas
    Submitted May 23, 2005
  • Reply to Zaidat et al
    • Wengui Yu, University of California, San Francisco, Parnassus Avenue, CA 94143-0114
    • Wade S. Smith, Vineeta Singh, Nerissa U. Ko, Sean P. Cullen, Christopher F. Dowd, Van V. Halbach, and Randall T. Higashida
    Submitted May 23, 2005
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me

Recommended articles